Key result
Intravenous infusion of saralasin decreased blood pressure only in the 1 subject with elevated resting plasma renin activity, with no relevant hemodynamic changes in the 10 subjects with normal renin.
Why the study?
Does intravenous saralasin alter hemodynamics and blood pressure in patients with hypertensive non-uraemic chronic renal disease?
Population
11 subjects with hypertensive chronic non-uraemic renal disease
Comparison
Intravenous infusion of saralasin in a rising… vs Baseline (pre-infusion control levels)
Design
Case_series
Follow-up
1 hour
Authors
Loading...
May guide renin-stratified testing in non-uraemic renal hypertension; leaves open whether angiotensin blockade benefits normal-renin patients.
Does intravenous saralasin alter hemodynamics and blood pressure in patients with hypertensive non-uraemic chronic renal disease?
Angiotensin plays an active role in elevating blood pressure in chronic non-uraemic renal disease only when plasma renin activity is raised.
Brod et al. (2008) studied chronic non-uraemic renal disease (n=11). Saralasin was evaluated on blood pressure, central haemodynamics, forearm blood flow and venous distensibility. Intravenous infusion of saralasin decreased blood pressure only in the 1 subject with elevated resting plasma renin activity, with no relevant hemodynamic changes in the 10 subjects with normal renin.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: